The diagnosis and treatment of pulmonary inflammatory myofibroblastic tumor: a single center retrospective study and literature review
10.3760/cma.j.cn112434-20210116-00017
- VernacularTitle:肺部炎性肌纤维母细胞瘤的诊疗：单中心回顾性研究并文献综述
- Author:
Ke ZHAO
1
;
Jiaqi ZHANG
;
Ke RAO
;
Lei LIU
;
Guige WANG
;
Wenliang BAI
;
Mengxin ZHOU
;
Xuehan GAO
;
Shanqing LI
Author Information
1. 中国医学科学院 北京协和医院胸外科，北京 100730
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2022;38(6):380-384
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary inflammatory myofibroblastic tumor (PIMT) is a rare lung tumor that is poorly understood by clinicians. Based on the data of patients with PIMT in our center, a comprehensive search and a brief summary analysis of previous reports of the disease were carried out in this article. PIMTs were more likely to be present in male patients and in the right lung, and their clinical and radiographic findings were heterogeneous. Surgery is the most important treatment method, and complete resection is of great significance to the prognosis of patients. Targeted therapy represented by crizotinib may be helpful for patients with positive ALK mutations.
